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Abstract
Variability is a characteristic feature of asthma, and the aim of asthma management is to eliminate or minimise disease variability.
Controlled asthma shows little or no variability, and is achievable and sustainable in the majority of patients. New international guidelines
recommend control-driven management rather than management based on disease severity. Good asthma control is associated with
reductions in patients’ perception of the asthma burden, reduced healthcare resource utilisation, lower levels of impairment/restriction,
normal quality of life, and low risk of exacerbations. Asthma control involves the control of several outcomes. Its assessment should
include components relevant to achievement of best possible clinical control and reduction of future risk of adverse outcomes. Focusing
on a single or a few outcomes can lead to incorrect control assessment and increased risk of under-treatment. Several validated asthma
control assessment tools have been developed to facilitate correct assessment of the level of control in clinical practice. It is hoped that
focusing on control will reduce the frequency of sub-optimal treatment in the primary care setting. Further validation of the best way to
assess control easily and accurately, and the implementation of control-driven management, are the two most important challenges for
the future of asthma management.
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Introduction
The initial Global INitiative for Asthma (GINA) treatment
guideline published in 1993 was based on disease severity
grading: intermittent, mild persistent, moderate persistent
and severe persistent asthma. Since then several studies have
shown that guideline-defined asthma control is achievable in
most patients, and that achievement of good control is
associated with improved health status.1-3 Therefore, in the
latest GINA guideline, treatment recommendations are based
on the level of asthma control rather than disease severity.4 In
the control-driven approach, the attainment and
maintenance of asthma control are the key elements that
drive patient management.4 To achieve this, patients should
be assessed, and treatment tailored and adjusted in regular
cycles based on their asthma control status (see Figure 1).
When the condition is not controlled, treatment should be
stepped up until control is achieved and maintained for at
least three months, at which point a step down in treatment
can be considered. 
This paper presents the background for the change in
treatment approach adopted by the GINA guideline. The area
is complex since there are no consistently accepted definitions
for asthma control, severity, or exacerbations. However, some
useful definitions have recently been recommended by a joint
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task force of the American Thoracic Society (ATS) and
European Respiratory Society (ERS):5
● Asthma severity is defined as the difficulty in controlling
asthma with treatment after exclusion of modifiable factors
such as poor adherence, smoking, and co-morbidities.
Severity largely reflects the required level of treatment and
the activity of the underlying disease state during treatment. 
● Asthma control encompasses not only the patient’s recent
clinical state (symptoms, night waking, reliever use, and lung
function), but also considers their ‘‘future risk’’ – that is, their
potential for experiencing adverse outcomes, such as loss of
control in the near or distant future, exacerbations,
accelerated decline in lung function, or treatment-related
side effects. It is emphasised that even if current poor control
predicts future poor control and health care utilisation, other
pathologic and physiologic measures, independent of the
level of current clinical control, also influence future risk.5
Why ‘control’ rather than ‘severity’?
Severity grading is complex and not widely used in clinical
practice.6,7 Cross-sectional surveys from various countries have
shown that the use of inhaled corticosteroids (ICS) and quick
reliever medications is independent of patients’ asthma severity
grading.8,9 No correlation is seen between asthma severity and
regular use of ICS. In a European survey of patients with
persistent asthma symptoms, ICS were used by only 25% of
adults with severe asthma, 23% of those with moderate asthma
and 28% of those with mild asthma; the corresponding figures
for children were 26%, 33% and 33%, respectively.8 Similar
findings indicative of poor asthma control and a lack of
correlation between ICS use and severity were recorded in 3207
patients interviewed across the Asia–Pacific region in the Asthma
Insights and Reality in Asia–Pacific (AIRAP) study.9 In this study,
the use of ICS was 18%, 17%, 13% and 12% in severe
persistent, moderate persistent, mild persistent and mild
intermittent7 asthma patients, respectively. Patients often
underestimate disease severity and overestimate control, with
the result that 50% of those interviewed in the European study
with severe and persistent asthma symptoms considered their
condition to be completely or well controlled despite poor health
status and high levels of healthcare resource utilisation.8 
Asthma severity is not fixed. It fluctuates over time and is
enhanced by various trigger factors such as seasonal allergen
exposure, infections and treatment. Thus, over a three-month
period, placebo-treated patients with moderate asthma severity
at baseline could be classified as having severe asthma 6% of the
time, mild asthma 14% of the time, and intermittent asthma 9%
of the time.10 
Accurate disease severity assessment is even more complex in
patients who are already on regular controller medication.11 Liard
and colleagues used the GINA guideline to define asthma
severity in more than 4000 patients and found that the
classification rules were complex and not clinically useful because
of frequent over- and under-estimation of severity, even when a
“symptom + forced expiratory volume in one second (FEV1) +
medication” classification was used.11 Respiratory specialists have
been reported to disagree markedly when classifying asthma
severity.12,13 The differences between severity and control have
recently been discussed in detail.5,14
Patients with severe symptoms and impairment (particularly
Level of control
Controlled
Partially
controlled
Uncontrolled
Exacerbation
Time (months)
Treatment adequate
Consider step-up
controller
Treat or step-up
controller medication
Treat as exacerbation
Figure 1.  Asthma management: A treatment algorithm based on GINA guidelines.4 In partially controlled patients the
decision to step up treatment is influenced by the level of treatment the patient is already receiving and the patient’s
demands. If partial control has been achieved on a low daily dose of inhaled corticosteroid, stepping up the daily
controller treatment is more likely than if the patient is partially controlled on a high daily controller treatment or if
they are using multiple drugs. The control level should be re-assessed regularly (every 3–6 months) and at each
assessment it should be decided whether the current treatment should be continued or stepped down.
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children) can still have normal lung function.12,13,15-17 This discord
between the clinical presentation and level of lung function –
which is an important factor in the severity grading – can
complicate the assessment of severity, leading to
underestimation of disease severity and under-treatment with
subsequent poor asthma control. This may contribute to the
findings that a substantial number of children with fatal asthma
exacerbations had been assessed as having mild disease and
were not prescribed regular controller treatment.12,13 Thus, in one
study of 61 patients (mainly children) who experienced fatal
asthma exacerbations over a 7-year period, only 5% of those
who died were using long-term control medications.12
Asthma control is achievable in most
patients 
Clinical evidence suggests that good asthma control is achievable
for the vast majority of patients, including adults and
adolescents.2,3,18 In one study, adult and adolescent patients with
markedly uncontrolled asthma were treated with either
fluticasone propionate (FP) or salmeterol plus FP combination
(SFC) for 1 year18 to assess the proportion of patients that could
achieve total- or well-controlled asthma. The vast majority of the
patients had severe persistent asthma at study entry. The level of
control was defined by a composite measure (based on
international guidelines) that included daytime symptoms, use of
rescue medication, peak expiratory flow, night-time awakening,
exacerbations, emergency room visits and treatment-related
adverse events. Treatment was stepped up at 3-month intervals
until either patients achieved total control or the maximum dose
of study medication (1000 mcg FP per day) was reached. At the
end of the study period, approximately 70% of patients had
asthma that was either well controlled or totally controlled.
Moreover, improvements in at least one clinical outcome were
seen in more than 90% of patients classified as not well-
controlled.2 Present and former smoking was identified as the
most important factors for not achieving control.2 Further
analysis showed that in patients who were ICS-naïve at study
entry, and who achieved total asthma control and maintained
this control status over long periods, only 2.8% had reverted to
being not well-controlled (2.8%).19 These results confirmed that,
in the vast majority of patients control can be maintained as long
as the treatment is continued.
Other large studies in children and adults have corroborated
these findings for mild and moderate asthma.3,20 In the inhaled
Steroid Treatment As Regular Therapy in early asthma (START)
study, regular asthma treatment with budesonide for three years
resulted in long-term symptom resolution in more than 90% of
patients, and during the last year of the study the number of
exacerbations was negligible.3 In the CAMP study budesonide
treatment for 4.5 years reduced the number of days with
symptoms to less than two per week, and the need for rescue
medication from 10 to three puffs per week. In addition the
number of nocturnal awakenings was reduced to negligible
levels.20
Level of asthma control is important
A characteristic feature of asthma is the variability of the
condition with marked fluctuations in symptoms and asthma
control over time. An important aim of asthma management,
therefore, is to minimise disease variability to enable patients to
live a healthy life. The GOAL study demonstrated that this is
achievable in the majority of patients; around 90% of the
patients who achieved well-controlled or totally controlled
asthma during phase 1 of the study remained at least well-
controlled at the end of the one-year study and in these patients
exacerbations were very rare (<0.4% probability).19 Importantly,
disease stability was independent of the medication taken (FP or
SFC) or disease severity. Only the level of asthma control was
important for the stability of the disease and the risk of having
an exacerbation (see Figure 2).
In agreement with these findings, other studies have shown
that the use of healthcare resources, the level of lifestyle
impairment, and quality of life, are all closely linked to the level
of asthma control: the better the control, the less impairment,
the lower the use of healthcare resources, and the higher the
quality of life.1,21-28 A 2-year assessment of approximately 4000
patients with difficult-to-treat or severe asthma reported that
patients with uncontrolled asthma experienced a higher annual
mean number of work days lost (7.1 vs 0.4), school days lost (9.1
vs 0.1) and physician visits (5.6 vs 2.4), compared with patients
who had controlled asthma.24 Furthermore, the costs associated
with the condition were directly related to the level of control;
costs for uncontrolled patients were more than twice the costs of
controlled patients (US$14,212 vs US$6452; P<0.0001). These
findings were corroborated in a recent report by Chapman et al.
in approximately 10,500 patients presenting in general practices
in Canada;21 poor daily control was associated with more
hospitalisations, emergency room visits, unscheduled doctor
visits and other healthcare contacts.
Most of these studies emphasised the importance of the level
of asthma control rather than the disease severity or treatment
modality for the quality of life, risk of exacerbations, burden of
disease and impairment in lifestyle. Thus, patients with severe
asthma will experience the same quality of life and disease
stability as patients with mild disease providing that their level of
asthma control is similar. The achievement of asthma control in
the two groups (severe or mild asthma) may require different
treatment intensities, but the impact of the disease on daily
lifestyle is likely to be the same after the disease has become
controlled. Thus, the level of control is a good predictor of a
variety of asthma outcomes that are clinically important to both
the patient and society.   
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How should asthma control be defined
and assessed?
When a new parameter (control level) is used to guide
treatment, the definition of asthma control becomes important.
As mentioned previously, physicians and patients tend to
overestimate the level of asthma control.8,9,21,29,30 Moreover,
physicians use various parameters to assess control and,
therefore, might evaluate control differently.29,31 Unless a control
definition that is clinically relevant and easy to use for both
healthcare professionals and patients in daily management is
developed, the risk of under-treatment will still remain.
Therefore, several validated scoring systems and control
definitions that fulfil these criteria have been developed to
facilitate accurate measurement of the level of asthma
control.23,30-34 Some, but not all of these instruments include
measures of lung function.6 All include a combination of several
clinical variables to assign a composite score to distinguish
between the different levels of asthma control and some are
being positioned for use by patients, and are available on the
internet and in several languages.
From the validation of the various asthma control tests, and
from the findings in the GOAL study19, it has become clear that
focusing on a single or a few outcomes can lead to over-
assessment of control with a subsequent risk of under-
treatment.35 Different outcomes may require different treatment
intensities, and the rate of response of individual asthma
measures varies. Therefore, evaluation of control using any
single measure is likely to overestimate asthma control. Thus,
after 12 weeks of treatment in the GOAL study, the proportion
of patients who achieved control of an individual clinical criterion
was always higher than the proportion who achieved control
defined by a composite measure (no nocturnal awakenings was
achieved by around 70%; a peak expiratory flow (PEF) >80%
predicted every day was achieved by around 50%; no rescue
medication use was reported in 42%; no daytime symptoms
were in 30%). In contrast, total control defined by a composite
measure was achieved by only around 18% at that time. This
supports the idea that treatment should be continued until
composite control is reached rather than control of one or a few
individual outcomes. 
Focusing on a single outcome, however, might not lead to
improvements in other endpoints and could therefore result in
under-treatment (Figures 3 and 4). This is illustrated by the
findings in a recent 12-month, double-blind study in patients
with symptomatic asthma treated with budesonide/formoterol
morning and evening plus reliever therapy with either
budesonide/formoterol, formoterol alone or terbutaline alone.36
Time to first severe exacerbation (the primary endpoint) was
significantly longer and the rate of severe exacerbations was
markedly lower in the as-needed budesonide/formoterol group
compared with those treated with formoterol or terbutaline
alone. Statistically significant improvements were also seen in
other outcomes – however, compared with the effects on
exacerbations these effects were small. Patients treated with the
budesonide/formoterol as-needed combination experienced 1.1
mild exacerbations per week, nocturnal awakening on one night
per week, and had uncontrolled asthma for two out of three
days. So, in spite of a good effect on the frequency of severe
exacerbations the majority of patients still had uncontrolled
asthma as defined by a composite score. As a result, no effect
Figure 2.  The influence of the level of asthma control on the risk of having an asthma exacerbation in patients treated
with fluticasone propionate (blue bars) or fluticasone propionate-serevent combination (purple bars).13 The level of
asthma control determined the risk of having an exacerbation – the better the control the lower the risk. In patients at
the same asthma control level the risk of an exacerbation was independent of the medication taken (though more
patients on the combination treatment achieved well and totally controlled asthma. Similarly, the use of healthcare
resources, the level of lifestyle restrictions and quality of life have been closely linked to the level of asthma control:
the better the control, the less the impairment, the lower the use of healthcare resources, and the higher the quality
of life.
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was seen on the patients’ asthma quality of life questionnaire in
which only 30% of patients scored normal values.
Given these findings, composite measures of control –
controlled, partially controlled or uncontrolled asthma – are
recommended in the latest GINA guideline. The components of
control include daytime symptoms, limitations of activities,
nocturnal symptoms/awakening, the need for reliever/rescue
medication, lung function and exacerbations (Table 1).37
Although these guidelines considered the recommendations as
being a non-validated working model at the time of publication,
composite measures of totally controlled and well-controlled
asthma based on GINA and the National Institute of Health
guidelines have more recently been validated as functional
indices of disease control.38,39 The study by Thomas and
colleagues found that an ACT score of <19 correctly predicted
GINA-defined partly controlled/uncontrolled asthma 94% of the
time, while an ACT score of >20 predicted GINA-defined
controlled asthma only 51% of the time.40 Thus, a normal ACT
score did not exclude poor asthma control whereas a reduced
score strongly suggested poor asthma control. When
exacerbations were removed from the definition of asthma
control, a score >20 predicted GINA-defined asthma control
71.6% of the time. Therefore, more work is needed to assess
how best to use exacerbations in the definition of, and how to
define the best and most simple way to assess, asthma control in
clinical practice – in particular in children and in patients with
mild asthma, many of whom have adapted their lifestyle to
ensure fewer symptoms at the expense of limiting activities in
their daily life.
The joint ATS/ERS Task Force has recently listed a variety of
asthma outcomes relevant for control assessment in the daily
clinic.5 These include symptom-free days (symptom/reliever/lung
function diary), pre- and post-bronchodilator FEV1, composite
scores, quality of life, treatment side-effects and exacerbations
(oral steroids, emergency room visits and hospitalisations within
last four weeks). 
Although the present recommendations are likely to make
the assessment of control easier, it has not yet been
demonstrated how to resolve patients’ poor perception of
asthma symptoms. Therefore, overcoming the obstacles with
accurate assessment and implementation of control-driven
treatment constitute some important challenges for the future. It
is hoped that the focus on control will reduce the frequency of
sub-optimal treatment in the primary care setting. Recent
findings suggest that lack of control can be recognised by
physicians in general practice with the use of standardised
Death 
Severe 
exacerbation 
Mild and moderate 
exacerbations 
Days with poor control 
Puffs of rescue medication 
No. of night-time awakenings 
Quality of life - Restrictions/Impairment 
Airway inflammation and remodelling 
Bronchial hyper-responsiveness 
Decline in lung function 
 
1 
50–80 
300 
    450 
        50 
???? 
Figure 3.  Frequency of different asthma outcomes used
in clinical trials. Outcomes at the top of the pyramid are
very serious but also very rare compared with the
outcomes in the lower part of the pyramid. Thus for each
time one severe exacerbation is seen in large clinical
trials around 50 mild exercabations and 300 days with
poor asthma control will occur in that study population.
The ratios between the various outcomes have been
calculated from data in published clinical studies
including more than 10,000 patients. It is obvious that
symptoms are by far the most common problem for the
patients. Controlling symptoms will also reduce the risk
of mild and severe exacerbations and improve the
patient’s quality of life. Therefore, control of daily
symptoms is an important outcome in asthma
management. 
Time (months)
Controlled
Partially
controlled
Uncontrolled
Exacerbation
Figure 4.  Importance of using a composite score rather
than a single outcome such as exacerbations when
assessing the effect of treatment and the level of asthma
control illustrated by one case. The black line illustrates
the situation before treatment. The patient is
uncontrolled most of the time and experiences 5
exacerbations over a year. After treatment (gray line)
there are no longer any exacerbations and the clinical
condition is markedly improved. However, when the
control level is assessed using the outcomes
recommended in Table 1 it becomes obvious that the
disease, in spite of the marked improvements, is still
insufficiently controlled and further adjustment of
treatment warranted.   
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questionnaires – and then, after control status has been
identified, the physician is likely to consider appropriate changes
to therapy.21 
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